Terauchi, Y., Fujiwara, H., Kurihara, Y., Suganami, H., Tamura, M., Senda, M., . . . Kaku, K. (2019). Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study. J Diabetes Investig.

Terauchi, Yasuo, Hisataka Fujiwara, Yuji Kurihara, Hideki Suganami, Masahiro Tamura, Masayuki Senda, Ryoji Gunji, و Kohei Kaku. "Long‐term Safety and Efficacy of the Sodium–glucose Cotransporter 2 Inhibitor, Tofogliflozin, Added On Glucagon‐like Peptide‐1 Receptor Agonist in Japanese Patients With Type 2 Diabetes Mellitus: A 52‐week Open‐label, Multicenter, Post‐marketing Clinical Study." J Diabetes Investig 2019.

Terauchi, Yasuo, et al. "Long‐term Safety and Efficacy of the Sodium–glucose Cotransporter 2 Inhibitor, Tofogliflozin, Added On Glucagon‐like Peptide‐1 Receptor Agonist in Japanese Patients With Type 2 Diabetes Mellitus: A 52‐week Open‐label, Multicenter, Post‐marketing Clinical Study." J Diabetes Investig 2019.